
Optimizing Heart Failure Outcomes with Intravenous Iron: Adaptive Approaches for Effective Diagnosis and Treatment of Iron Deficiency in HFrEF
This timely and dynamic educational activity will begin with a foundational circumscription of iron deficiency (ID) pathophysiology and clinical gravity in heart failure (HF), particularly in heart failure with reduced ejection fraction (HFrEF), as well as the impact of elevated hepcidin on iron supplementation strategies. An expert-led exploration of clinical trial data for intravenous (IV) iron therapies in HF and recently-updated expert consensus HF management guidelines will follow, with emphasis on the emerging role of IV iron on improvement of patient functional capacity, quality of life, and hard clinical endpoints in HFrEF. Finally, activity attendees will apply all they’ve learned in an interactive, case-based section that will highlight the improved safety and efficacy profiles of next-generation IV iron products, the importance of total dose infusions (TDIs), and the practical utility of digitalized checklists to ensure adherence to guideline-directed medical therapy (GDMT) in HF, of which IV iron is quickly becoming a standard pillar of care.
Target Audience
Cardiologists and key members of their interprofessional and multidisciplinary care teams who manage patients with heart failure.
Registration for the 2022 HFSA Annual Scientific Meeting and an official name badge are required to attend this symposium.
Learning Objectives
- Summarize the basic principles of iron metabolism and absorption, with a focus on how these principles apply to treatment of iron deficiency (ID) in heart failure (HF), distinguishing between HFrEF and HFpEF in terms of presentation and treatment standards.
- Review the pivotal role of hepcidin in ID pathophysiology, especially in a hyperinflammatory condition like HF, and recognize the prognostic impact of ID, irrespective of concomitant anemia, on patient functional capacity, quality of life, and HF morbidity and mortality endpoints.
- Evaluate the fundamental utility of serum ferritin and transferrin saturation (TSAT) as laboratory indices for ID diagnosis, and differentiate the practical distinctions between functional and absolute ID in the setting of HF.
- Appraise completed, ongoing, and planned clinical trials of IV iron therapies for ID in HF, and discuss recent pivotal data readouts that have influenced current practice and informed consensus HF guideline statements (2021 ESC and 2022 ACC/AHA/HFSA).
- Compare and contrast FDA-approved IV iron agents, including updated label indications and dosing regimens, and understand how the nanoparticle design of next-generation IV iron products has dramatically improved safety profiles vs. older agents.
- Using a case-based format, analyze how inflammation impacts the comparative clinical utility of oral iron vs. IV iron in HF, and design real-world treatment strategies with IV iron that promote HF GDMT, incorporate novel tools, and optimize outcomes.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from American Regent.
Additional Information
Attachment | Size |
---|---|
![]() | 679 KB |
10 min Welcome
20 min Heart Failure Disease State Review: The Pathophysiology and Clinical Gravity of Concomitant Iron Deficiency
25 min A New Standard in Heart Failure Management: Ushering in the Era of Intravenous Iron as a Pillar of Care
25 min Cardiology Catalysts: Real-world Strategies for Closing the Iron Deficiency Chasm in HFrEF
10 min Q&A/Panel Discussion
Javed Butler, MD, MPH, MBA (Activity Chair)
President, Baylor Scott and White Research Institute
Patrick H Lehan Chair in Cardiovascular Research
Professor and Chairman, Department of Medicine
University of Mississippi Medical Center
Jackson, MS
Stefan D. Anker, MD, PhD
Professor of Cardiology and Cachexia Research
Department of Cardiology
Charite University
Berlin, Germany
Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
The Mary and Gordon Cain Chair and Professor of Medicine
Associate Provost of Faculty Affairs
Senior Associate Dean of Faculty Development
Director, Winters Center for Heart Failure Research
Assoc. Director, Cardiovascular Research Institute
Vice-Chair of Medicine, Baylor College of Medicine
Medicine Chief, DeBakey VA Medical Center
Houston, TX
Muthiah Vaduganathan, MD, MPH
Co-Director, Center for Cardiometabolic Implementation Science
Harvard Medical School
Brigham and Women’s Hospital
Cardiovascular Medicine
Boston, MA
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Planners:
Bryan Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Muthiah Vaduganathan, MD, MPH—has disclosed that he receives research support from AstraZeneca, Bayer AG, Boeringer Ingelheim, Galmed, Impulse Dynamics, Novartis, Occlutech, and Roche Diagnostics; is on the advisory panel for American Regent, Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; and is on the speaker’s bureau for Novartis and Roche Diagnostics.
Authors/Faculty:
Stefan D. Anker, MD, PhD—has disclosed that he is a consultant for AstraZeneca, Bayer AG, Boehringer Ingelheim, and Novartis; and receives grant/research support from Abbott Laboratories and Vifor.
Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP—has disclosed that she is on the advisory panel of Amgen, AstraZeneca, and Boehringer Ingelheim; was on the advisory panel of Baxter, Sanofi-Aventis, and scPharmaceuticals; and receives other financial or material support from Abbott Laboratories, Cardurion Pharmaceuticals, LivaNova, Renovacor, Respicardia, and Vifor Pharma.
Javed Butler, MD, MPH, MBA—has disclosed that he is a consultant for Abbott, Adrenomed, Amgen, Applied Therapeutics, Array, AstraZeneca, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, G3 Pharmacueticals, Impulse Dynamics, Innolife, Janssen, Luitpold Pharmacueticals, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, and Vifor Pharma; and is on the speaker’s bureau for AstraZeneca, Boehringer Ingelheim, Janssen, and Novartis.
Muthiah Vaduganathan, MD, MPH—has disclosed that he receives research support from AstraZeneca, Bayer AG, Boeringer Ingelheim, Galmed, Impulse Dynamics, Novartis, Occlutech, and Roche Diagnostics; is on the advisory panel for American Regent, Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; and is on the speaker’s bureau for Novartis and Roche Diagnostics.
Peer Reviewers:
Jennifer Cook–has disclosed that she is an employee of Itmar Medical.
Robert Didomenico–has disclosed that he is on the advisory panel for ABIOMED and PhaseBio and he receives grant/research support from CSL Behring.
Daniel Garry–has disclosed that he is a board member for NorthStar Genomics.
David Lanfear–has disclosed that he is a consultant for Abbott Laboratories, Amgen, AstraZeneca, Janssen, Martin Pharmaceuticals. Receives grant/research support from Lilly and SomaLogic and is on the advisory panetl for Cytokinetics and Illumina.
Cheryl Westlake–has no relevant financial relationships to disclose in relation to the content of this activity.
CEC Staff:
Bryan Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, this activity has been planned and implemented by the Heart Failure Society of America and Creative Educational Concepts. The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians: The Heart Failure Society of America designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum 1.5 contact hours.
Learners should claim only the credit commensurate with the extent of their participation in the activity.